---
title: "Roivant Sciences | 10-K: FY2026 Revenue Misses Estimate at USD 8.26 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287055439.md"
datetime: "2026-05-20T11:21:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287055439.md)
  - [en](https://longbridge.com/en/news/287055439.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287055439.md)
---

# Roivant Sciences | 10-K: FY2026 Revenue Misses Estimate at USD 8.26 M

Revenue: As of FY2026, the actual value is USD 8.26 M, missing the estimate of USD 9.045 M.

EPS: As of FY2026, the actual value is USD -0.54, beating the estimate of USD -1.2444.

EBIT: As of FY2026, the actual value is USD -693.18 M.

#### Consolidated Financial Position

As of March 31, 2026, Roivant Sciences Ltd. reported consolidated cash, cash equivalents, and marketable securities of $4.3 billion, with an accumulated deficit of approximately $501.8 million at the same date, supporting a cash runway into profitability.

#### Share Repurchase Program

For the twelve months ended March 31, 2026, Roivant Sciences Ltd. repurchased approximately 24.0 million common shares for an aggregate repurchase price of approximately $314.9 million.

#### Patent Infringement Settlement

Roivant Sciences Ltd. announced a $2.25 billion global settlement with Moderna, resolving patent-infringement litigation. Moderna is scheduled to pay Genevant and Arbutus $950 million in July 2026, with an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.

#### Vant Ownership (as of March 31, 2026)

-   **Priovant**: Roivant Sciences Ltd. owned 72% on a basic ownership basis and 66% on a fully diluted basis.
-   **Immunovant**: Roivant Sciences Ltd. owned 56% on a basic ownership basis and 52% on a fully diluted basis.
-   **Pulmovant**: Roivant Sciences Ltd. owned 97% on a basic ownership basis and 90% on a fully diluted basis.
-   **Genevant**: Roivant Sciences Ltd. owned 83% on a basic ownership basis and 64% on a fully diluted basis.
-   **Covant**: Roivant Sciences Ltd. owned 94% on a basic ownership basis and 91% on a fully diluted basis.
-   **Arbutus**: Roivant Sciences Ltd. owned 20% on a basic ownership basis and 19% on a fully diluted basis.

#### Vant Milestone & Royalty Payments (Summary of Select Potential Future Obligations)

-   **Priovant / Pfizer**: Potential mid-tens-of-millions sales milestone payment if aggregate net sales exceed a mid-hundreds-of-millions amount, along with tiered sub-teens royalty on net sales. Pfizer is also obligated to pay Priovant a low tens-of-millions milestone if its net sales outside Priovant’s territory exceed a mid-hundreds-of-millions amount, plus tiered high single-digit to sub-teens royalty on net sales outside Priovant’s territory.
-   **Immunovant / HanAll**: Up to an aggregate of $420.0 million in future contingent payments upon achievement of certain regulatory and sales milestone events, plus tiered royalties ranging from mid-single digits to mid-teens percentage of net sales of licensed products. Immunovant Sciences GmbH (ISG) previously paid an aggregate purchase price of $37.8 million to RSG in December 2018 for rights under the HanAll Agreement.
-   **Pulmovant / Bayer**: Up to an aggregate of $280 million upon achievement of certain development, regulatory, and net sales milestone events, plus tiered high-single-digits royalty on annual net sales of licensed products. Pulmovant made an initial payment of approximately $14 million to Bayer.
-   **Genevant / Arbutus**: Up to 20% of Royalty-Related Receipts from sublicenses or collaborations, or tiered low single-digit royalties on net sales by sublicensees. Arbutus is entitled to 20% of proceeds from patent infringement actions or tiered low single-digit royalties on net sales of the infringing product after deducting litigation costs.

#### Outlook / Guidance

Roivant Sciences Ltd. anticipates ongoing announcements for new mid/late-stage in-licensing opportunities. The company expects an FDA decision on brepocitinib in dermatomyositis and its commercial launch by the end of September 2026. Topline data from various Phase 2 and Phase 3 trials for mosliciguat and IMVT-1402 are projected between the second half of 2026 and 2028.

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Artivion Completes Acquisition of Endospan Ltd. | AORT Stock News](https://longbridge.com/en/news/286758893.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Nu Holdings Ltd. Reports First Quarter 2026 Financial Results | NU Stock News](https://longbridge.com/en/news/286474014.md)